This tutorial will provide an overview of the monitoring strategies for patients at risk of cardiomyopathy as a consequence of cancer therapy. Algorithms for monitoring patients who are actively receiving anthracyclines or trastuzumab therapy will be reviewed as well as the surveillance of survivors following exposure to these medications or radiation therapy. These aspects are becoming an increasingly important aspect for cancer survivorship programs.
- Integrate cardiac surveillance algorithms into the care of patients receiving active cancer therapy
- Apply current monitoring recommendations for cancer survivors
- Recognize the main modes of cardiac monitoring and their limitations
Joerg Herrmann, M.D.
Associate Professor of Medicine
Division of Cardiovascular Diseases
Mayo Clinic, Rochester, MN
$40 - Streaming Video
$50 - Streaming Video and DVD